Summary
Some high-level claims are consistent with the provided label excerpts (indication, PDE4 mechanism, not for acute bronchospasm, psychiatric events, weight loss/monitoring, dosing schedule, and CYP inducer interaction). However, several claims cannot be fully verified from the supplied excerpts (e.g., specific inflammatory signaling wording, common side effect list items like insomnia/headache, and ‘clinicians commonly use alongside’ inhaled therapies), and one claim conflicts with label dosing initiation detail (therapeutic dose statement).
Category Scores
Accurate Statements
Daliresp is the brand name for roflumilast.
Label excerpt: “The active ingredient in DALIRESP tablets is roflumilast.” (Section 11 DESCRIPTION)
Daliresp is a prescription medicine used for chronic obstructive pulmonary disease (COPD).
Label excerpt: “DALIRESP® is indicated as a treatment to reduce the risk of COPD exacerbations…” (Section 1 INDICATIONS AND USAGE)
Daliresp is intended for people with COPD who have chronic bronchitis and a history of frequent exacerbations to help reduce exacerbations.
Label excerpt: “...severe COPD associated with chronic bronchitis and a history of exacerbations.” (Section 1 INDICATIONS AND USAGE)
Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor.
Label excerpt: “Roflumilast...are selective inhibitors of phosphodiesterase 4 (PDE4).” (Section 12.1 Mechanism of Action)
Roflumilast can worsen psychiatric symptoms.
Label excerpt: “Treatment with DALIRESP is associated with an increase in psychiatric adverse reactions.” (Section 5.2 Psychiatric Events including Suicidality)
Roflumilast may cause gastrointestinal side effects.
Label excerpt: “The most common adverse reactions that led to discontinuation of DALIRESP were diarrhea...and nausea...” (Section 6.1 Adverse Reactions in Clinical Studies)
Because weight loss can be significant for some patients on Daliresp, clinicians monitor weight during treatment.
Label excerpt: “Patients treated with DALIRESP should have their weight monitored regularly.” (Section 5.3 Weight Decrease)
The prescribed dose of Daliresp depends on the product strength and the clinician’s instructions.
Label excerpts: “maintenance dose...one 500 micrograms (mcg) tablet per day” and “Starting treatment with...250 mcg once daily for 4 weeks and increasing to...500 mcg once daily thereafter...” (Section 2 DOSAGE AND ADMINISTRATION)
Roflumilast is used to reduce the number of COPD exacerbations over time rather than to act like a rescue inhaler during sudden breathing trouble.
Label excerpt: “DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm.” (Section 5.1 Treatment of Acute Bronchospasm) and “...reduce the risk of COPD exacerbations...” (Section 1 INDICATIONS AND USAGE)
Roflumilast can interact with other drugs that affect liver metabolism.
Label excerpts describe metabolism via CYP3A4/CYP1A2 and interaction with CYP inducers: “A major step in roflumilast metabolism is... by CYP3A4 and CYP1A2.” (Section 5.4 Drug Interactions) and “Drugs that induce... decrease systemic exposure...” (Section 7.1)
Drug interactions involving liver metabolism may change roflumilast levels or side-effect risk.
Label excerpts: strong CYP inducers “resulted in a reduction in exposure” and may decrease effectiveness (Section 5.4; 7.1). CYP inhibitors “may increase roflumilast systemic exposure and may result in increased adverse reactions.” (Section 7.2)
Roflumilast targets exacerbation risk through an oral anti-inflammatory mechanism (PDE4 inhibition).
Label excerpt: PDE4 mechanism of action (Section 12.1). Indication to reduce exacerbations (Section 1).
Unsupported Statements
Roflumast works by reducing inflammation in the airways.
Provided excerpts do not state ‘reducing inflammation in the airways’; they describe PDE4 inhibition and increased intracellular cyclic AMP.
Roflumilast helps lower inflammatory signaling that contributes to COPD symptoms and flare-ups.
No provided excerpt uses ‘inflammatory signaling’ wording; label excerpts only specify PDE4 inhibition mechanism and exacerbation risk reduction.
Roflumilast is intended for people with COPD who have chronic bronchitis and a history of frequent exacerbations to help reduce exacerbations.
Label excerpt specifies ‘severe COPD associated with chronic bronchitis and a history of exacerbations,’ but ‘frequent exacerbations’ wording is not present in the supplied excerpts.
Commonly reported side effects of Daliresp include diarrhea, nausea, and weight loss.
Label excerpts confirm diarrhea and nausea as common adverse reactions and weight loss as a common adverse reaction, but the prompt’s phrase ‘commonly reported side effects’ is not directly supported as a single ‘commonly reported side effects’ list in the supplied excerpt.
Commonly reported side effects of Daliresp include headache and insomnia.
Headache and insomnia are not listed as common adverse reactions in the provided excerpts (insomnia appears as a warning symptom to monitor, not as a ‘commonly reported’ side effect in the excerpt).
The full benefit of Daliresp typically takes weeks of consistent use and follow-up.
The supplied excerpts do not provide a timeframe for time-to-benefit.
Clinicians commonly use roflumilast alongside inhaled COPD maintenance therapies.
No provided label excerpt states ‘commonly use’ or co-prescription with specific inhaled maintenance therapy.
Roflumilast is used alongside inhaled therapies such as inhaled corticosteroids, long-acting beta agonists, and/or long-acting muscarinic antagonists for patients with frequent exacerbations despite inhaler therapy.
No provided label excerpt describes specific co-therapies (ICS/LABA/LAMA) or criteria like ‘frequent exacerbations despite inhaler therapy.’
Whether a generic version of Daliresp is available depends on the country and pharmacy pricing.
The provided label excerpts do not address generic availability or country/pharmacy pricing.
Contradictions
Low
AI Statement
Daliresp is taken by mouth once daily.
Label Reference
Dose excerpt specifies “maintenance dose...one 500 micrograms...per day” and includes “Starting treatment...250 mcg once daily...increasing to...500 mcg once daily thereafter.” (Section 2).
Low
AI Statement
Roflumilast is taken by mouth once daily.
Label Reference
The provided excerpt does not explicitly state “by mouth” phrasing, only tablets/dosing per day; route is not directly quoted in the excerpts.
Low
AI Statement
The full benefit of Daliresp typically takes weeks of consistent use and follow-up.
Label Reference
No provided excerpt provides time-to-benefit; if interpreted as a labeled expectation, it is not supported. Contradiction is not provable from excerpts.
Important Omissions
Contraindication in moderate to severe liver impairment (Child-Pugh B or C).
Importance:
Moderate
Specific dosing initiation detail: 250 mcg once daily for 4 weeks and that 250 mcg per day is not the effective/therapeutic dose.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Overall risk is mainly driven by dosing/administration and missing contraindication information. Several claims are unsupported (co-therapy practices, common side effects list, time-to-benefit), but no direct label contradiction about safety-critical points is clearly established from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several safety/efficacy-adjacent assertions are not supported by the provided label excerpts (headache/insomnia as common side effects; time-to-benefit; common co-use with ICS/LABA/LAMA; generic availability). Contraindication information (liver impairment) is omitted and dosing nuance (250 mcg not therapeutic) is not reflected.
Suggested Improvement
Restrict statements to what the label excerpts support: COPD indication language; PDE4 mechanism; not for acute bronchospasm; psychiatric/weight loss warnings with monitoring; maintenance dose (500 mcg daily) and the 250 mcg starter period with the ‘not therapeutic’ note; CYP interaction framework; omit unsupported ‘common’ side-effect items and co-therapy/general generic availability claims unless present in the provided label text.